21-hydroxylase deficiency overview: Difference between revisions
No edit summary |
|||
| Line 8: | Line 8: | ||
'''Congenital adrenal hyperplasia due to [[21-hydroxylase]] deficiency''' ('''21-OH CAH''') accounts for about 95% of diagnosed cases of [[congenital adrenal hyperplasia]], and '''CAH''' in most contexts refers to 21-hydroxylase deficiency.<ref name="pmid10857554">{{cite journal| author=White PC, Speiser PW| title=Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. | journal=Endocr Rev | year= 2000 | volume= 21 | issue= 3 | pages= 245-91 | pmid=10857554 | doi=10.1210/edrv.21.3.0398 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10857554 }} </ref> | '''Congenital adrenal hyperplasia due to [[21-hydroxylase]] deficiency''' ('''21-OH CAH''') accounts for about 95% of diagnosed cases of [[congenital adrenal hyperplasia]], and '''CAH''' in most contexts refers to 21-hydroxylase deficiency.<ref name="pmid10857554">{{cite journal| author=White PC, Speiser PW| title=Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. | journal=Endocr Rev | year= 2000 | volume= 21 | issue= 3 | pages= 245-91 | pmid=10857554 | doi=10.1210/edrv.21.3.0398 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10857554 }} </ref> | ||
Congenital adrenal hyperplasia was first discovered by Luigi De Crecchio, an Italian anatomist. Congenital adrenal [[hyperplasia]] due to 21-hydroxylase deficiency is caused by mutations in the ''CYP21A2'' gene. It must be differentiated from other causes of adrenal hyperplasia such as 11-β hydroxylase deficiency and 17-α hydroxylase deficiency. Symptoms include [[dehydration]], [[vomiting]] and [[weight loss]], symptoms occur later may include [[virilization]] and [[infertility]]. | Congenital adrenal hyperplasia was first discovered by Luigi De Crecchio, an Italian anatomist. Congenital adrenal [[hyperplasia]] due to 21-hydroxylase deficiency is caused by mutations in the ''CYP21A2'' gene. It must be differentiated from other causes of adrenal hyperplasia such as 11-β hydroxylase deficiency and 17-α hydroxylase deficiency. Symptoms include [[dehydration]], [[vomiting]] and [[weight loss]], symptoms occur later may include [[virilization]] and [[infertility]]. | ||
The mainstay of therapy for 21-hydroxylase deficient congenital adrenal hyperplasia is [[glucocorticoid]] replacement. | The mainstay of therapy for 21-hydroxylase deficient congenital adrenal [[hyperplasia]] is [[glucocorticoid]] replacement. | ||
==Historical Perspective== | ==Historical Perspective== | ||
Revision as of 20:52, 17 September 2015
|
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency Microchapters |
|
Differentiating Congenital adrenal hyperplasia due to 21-hydroxylase deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
21-hydroxylase deficiency overview On the Web |
|
American Roentgen Ray Society Images of 21-hydroxylase deficiency overview |
|
Directions to Hospitals Treating Congenital adrenal hyperplasia due to 21-hydroxylase deficiency |
|
Risk calculators and risk factors for 21-hydroxylase deficiency overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Overview
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21-OH CAH) accounts for about 95% of diagnosed cases of congenital adrenal hyperplasia, and CAH in most contexts refers to 21-hydroxylase deficiency.[1] Congenital adrenal hyperplasia was first discovered by Luigi De Crecchio, an Italian anatomist. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency is caused by mutations in the CYP21A2 gene. It must be differentiated from other causes of adrenal hyperplasia such as 11-β hydroxylase deficiency and 17-α hydroxylase deficiency. Symptoms include dehydration, vomiting and weight loss, symptoms occur later may include virilization and infertility. The mainstay of therapy for 21-hydroxylase deficient congenital adrenal hyperplasia is glucocorticoid replacement.
Historical Perspective
Congenital adrenal hyperplasia was first discovered by Luigi De Crecchio, an Italian anatomist.
Pathophysiology
Development of congenital adrenal hyperplasia due to 21-hydroxylase deficiency is the result of defective P450c21 enzyme.
Causes
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency is caused by mutations in the CYP21A2 gene.
Differentiating congenital adrenal hyperplasia due to 21-hydroxylase deficiency from other diseases
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency must be differentiated from other causes of adrenal hyperplasia such as 11-β hydroxylase deficiency and 17-α hydroxylase deficiency.
Epidemiology and Demographics
The incidence of 21-hydroxlase deficient congenital adrenal hyperplasia is approximately 1 per 15,000 births.
Risk Factors
The most potent risk factor in the development of 21-hydroxylase deficient congenital adrenal hyperplasia is mutations in the CYP21A2 gene.
Screening
Natural History
The prognosis of 21-hydroxylase deficient congenital adrenal hyperplasia is generally good with treatment. Common complications of 21-hydroxylase deficient congenital adrenal hyperplasia include short stature, adrenal crisis, infertility, and precocious puberty.
Diagnosis
History and Symptoms
Symptoms of 21-hydroxylase deficient congenital adrenal hyperplasia include dehydration, vomiting and weight loss, symptoms occur later may include virilization and infertility.
Physical Examination
Patients with 21-hydroxylase deficient congenital adrenal hyperplasia usually appear underweight and dehydrated. Physical examination of patients with 21-hydroxylase deficient congenital adrenal hyperplasia is usually remarkable for hypotension .and virilization.
Laboratory Findings
Laboratory findings consistent with the diagnosis of 21-hydroxylase deficient congenital adrenal hyperplasia include hyponatremia, hyperkalemia, and low cortisol level.
CT Scan
MRI
Treatment
Medical therapy
The mainstay of therapy for 21-hydroxylase deficient congenital adrenal hyperplasia is glucocorticoid replacement.
Surgery
Overview
Surgery is not the first-line treatment option for patients with congenital adrenal hyperplasia due to 21-hydroxylase deficieny. Surgical reconstruction of abnormal genitalia is usually reserved for severely virilized girls.
Primary Prevention
Doctors often recommend genetic counseling for parents who have congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Secondary Prevention
Continued monitoring of hormone balance and careful readjustment of glucocorticoid dose is helpful in controlling fertility.
References
- ↑ White PC, Speiser PW (2000). "Congenital adrenal hyperplasia due to 21-hydroxylase deficiency". Endocr Rev. 21 (3): 245–91. doi:10.1210/edrv.21.3.0398. PMID 10857554.